Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CRDL
Upturn stock ratingUpturn stock rating

Cardiol Therapeutics Inc Class A (CRDL)

Upturn stock ratingUpturn stock rating
$1.36
Last Close (24-hour delay)
Profit since last BUY19.3%
upturn advisory
Consider higher Upturn Star rating
BUY since 33 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CRDL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $8.99

1 Year Target Price $8.99

Analysts Price Target For last 52 week
$8.99Target price
Low$0.77
Current$1.36
high$2.63

Analysis of Past Performance

Type Stock
Historic Profit 1.12%
Avg. Invested days 33
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 117.02M USD
Price to earnings Ratio -
1Y Target Price 8.99
Price to earnings Ratio -
1Y Target Price 8.99
Volume (30-day avg) 5
Beta 0.76
52 Weeks Range 0.77 - 2.63
Updated Date 06/30/2025
52 Weeks Range 0.77 - 2.63
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.34

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -89.03%
Return on Equity (TTM) -190.11%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 99641386
Price to Sales(TTM) 1069.35
Enterprise Value 99641386
Price to Sales(TTM) 1069.35
Enterprise Value to Revenue 178.81
Enterprise Value to EBITDA 0.3
Shares Outstanding 82649696
Shares Floating 79599950
Shares Outstanding 82649696
Shares Floating 79599950
Percent Insiders 4.35
Percent Institutions 10.26

Analyst Ratings

Rating 3
Target Price 8.99
Buy 4
Strong Buy 1
Buy 4
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cardiol Therapeutics Inc Class A

stock logo

Company Overview

overview logo History and Background

Cardiol Therapeutics Inc. is a biotechnology company focused on the research and clinical development of pharmaceutical cannabidiol (CBD) and other anti-inflammatory therapies for the treatment of cardiovascular disease. Founded in 2016, it has progressed through pre-clinical and clinical stages, focusing on developing therapies for heart failure, acute myocarditis, and recurrent pericarditis.

business area logo Core Business Areas

  • Pharmaceutical CBD Development: Focuses on developing pharmaceutically produced cannabidiol formulations for cardiovascular diseases.
  • Cardiovascular Disease Therapies: Research and development of therapies targeting inflammation and fibrosis in heart conditions like heart failure and myocarditis.

leadership logo Leadership and Structure

The company is led by a management team with expertise in pharmaceutical development and commercialization. The organizational structure includes research and development, clinical operations, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • CardiolRx: A pharmaceutically produced oral cannabidiol formulation. Currently undergoing clinical trials for acute myocarditis and recurrent pericarditis. Market share is currently zero, as the product is still in clinical development. Competitors include companies developing treatments for myocarditis and pericarditis using traditional pharmaceutical approaches, such as corticosteroids and colchicine.

Market Dynamics

industry overview logo Industry Overview

The cardiovascular disease market is large and growing, driven by aging populations and lifestyle factors. There's increasing interest in novel therapies that address unmet needs, particularly in inflammatory heart conditions.

Positioning

Cardiol Therapeutics is positioned as a specialty pharmaceutical company focused on developing CBD-based therapies for cardiovascular disease. Its competitive advantage lies in its pharmaceutical-grade CBD formulation and its focus on specific inflammatory heart conditions.

Total Addressable Market (TAM)

The TAM for cardiovascular disease therapies is estimated at hundreds of billions of dollars globally. Cardiol Therapeutics is positioned to address a segment of this market related to inflammatory heart conditions, which represents a significant opportunity.

Upturn SWOT Analysis

Strengths

  • Proprietary pharmaceutical CBD formulation
  • Focus on specific unmet needs in cardiovascular disease
  • Experienced management team
  • Strong intellectual property position

Weaknesses

  • Limited revenue generation (clinical-stage company)
  • Dependence on clinical trial success
  • Relatively small market capitalization
  • High cash burn rate

Opportunities

  • Successful clinical trial results leading to regulatory approval
  • Partnerships with larger pharmaceutical companies
  • Expansion into new cardiovascular indications
  • Increasing acceptance of CBD as a therapeutic agent

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Changes in the regulatory landscape for CBD products
  • Generic competition if the CBD based medicine becomes accepted.

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • PFE
  • BMY

Competitive Landscape

Cardiol Therapeutics competes with established pharmaceutical companies in the cardiovascular space, although its focus on CBD-based therapies differentiates it. Its smaller size and limited resources present challenges in competing with larger players.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by pre-clinical and clinical development milestones rather than revenue growth.

Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of CardiolRx or other pipeline products. Analyst estimates vary widely depending on these factors.

Recent Initiatives: Recent initiatives include advancing clinical trials for CardiolRx in acute myocarditis and recurrent pericarditis, and exploring partnerships with other companies.

Summary

Cardiol Therapeutics is a clinical-stage biotechnology company with a focus on pharmaceutical CBD therapies for cardiovascular diseases. It has strong intellectual property and an experienced team but faces risks associated with clinical trial outcomes and competition from larger pharmaceutical companies. Success hinges on the approval and commercialization of CardiolRx or other pipeline products. The company needs to secure partnerships or additional funding to progress.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cardiol Therapeutics Inc Class A

Exchange NASDAQ
Headquaters Oakville, ON, Canada
IPO Launch date 2019-01-15
President, CEO & Director Mr. David G. Elsley MBA
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 18
Full time employees 18

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.